



19<sup>th</sup> January 2024

To,  
The Manager,  
Department of Corporate Relations,  
BSE Limited,  
P J Towers, Dalal Street,  
Fort, Mumbai- 400001.  
**BSE Scrip Code 524518**

To,  
The Manager,  
Listing Department,  
National Stock Exchange of India Ltd,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra(E), Mumbai- 400051.  
**NSE Scrip Code: KREBSBIO**

**Sub: Intimation of Board Meeting under Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR”).**

Dear Sir/Madam,

Pursuant to Regulation 29 of the SEBI LODR, intimation is hereby given that the Meeting of the Board of Directors of the Company will be held on Monday, 12<sup>th</sup> February 2024, *inter-alia* to consider and approve the Unaudited Financial Results of the 3<sup>rd</sup> quarter and 9 months ended December 31, 2023 of the Financial year 2023-24.

Further, with reference to the above meeting of the Board of Directors, we have already informed you vide our letter dated 21<sup>st</sup> December 2023 that the trading window for dealing in the securities of the Company by the Insiders as defined under the SEBI (Prohibition of Insider Trading) Regulations, 2015 shall remain closed with effect from close of business hours on 31<sup>st</sup> December 2023 until 48 hours after the declaration of the Company Unaudited Financial Results for the 3<sup>rd</sup> quarter and 9 Months ended 31<sup>st</sup> December 2023.

We request you to take the above on record and disseminate the same on your website.

Thanking you,  
Yours faithfully,

For **Krebs Biochemicals and Industries Limited**

**Jitendra Shah**

Managing Director & CEO